Clinical Trial Update: Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares neoadjuvant toripalimab plus nab-paclitaxel and platinum against neoadjuvant docetaxel with cisplatin and 5-fluorouracil (DCF)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Abraxane (paclitaxel albumin-bound)
• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Status: NOT_YET_RECRUITING